Pfizer Inc. (PFE) News

Pfizer Inc. (PFE): $44.06

-0.28 (-0.63%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter PFE News Items

PFE News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

PFE News Highlights

  • PFE's 30 day story count now stands at 50.
  • Over the past 25 days, the trend for PFE's stories per day has been choppy and unclear. It has oscillated between 1 and 10.
  • The most mentioned tickers in articles about PFE are AMP, MRNA and TOP.

Latest PFE News From Around the Web

Below are the latest news stories about PFIZER INC that investors may wish to consider to help them evaluate PFE as an investment opportunity.

Better Buy: Novavax or BioNTech Stock?

The two companies, known for their vaccines, could see their businesses benefit from a yearly COVID-19 shot.

Yahoo | February 4, 2023

Pfizer Is Moving Beyond Covid. Why Its Stock Is a Buy.

With its packed pipeline, growing R&D spending, and potential deals and share buybacks, there's more to the drugmaker than the market realizes.

Yahoo | February 4, 2023

10 Hot Healthcare Stocks To Buy Now

In this article, we discuss the 10 hot healthcare stocks to buy now. If you want to read about some more hot healthcare stocks to buy now, go directly to 5 Hot Healthcare Stocks To Buy Now. The rise of consumer prices has often lagged behind healthcare inflation, which includes costs for doctor visits, surgeries, […]

Yahoo | February 3, 2023

UPDATE 1-China's CanSino confident its mRNA COVID vaccine as good as Moderna, Pfizer shots

CanSino Biologics Chief Executive Yu Xuefeng said on Friday he was confident his company's experimental COVID-19 vaccine using messenger RNA (mRNA) technology was as good as shots from Moderna and Pfizer-BioNTech. As the COVID-19 pandemic evolves in China after the country abandoned its zero-COVID policy in December, domestic companies like CanSino are racing to develop mRNA COVID vaccines. The country - which experienced a wave of infections across its 1.4 billion population after the sudden relaxation of COVID restrictions - has so far declined to use mRNA vaccines from abroad, and has yet to approve a domestic one that uses the technology.

Yahoo | February 3, 2023

China's CanSino confident its mRNA COVID vaccine as good as Moderna, Pfizer shots

CanSino Biologics CEO Yu Xuefeng said on Friday he was confident his company's experimental COVID-19 vaccine using messenger RNA (mRNA) technology was as good as shots from Moderna and Pfizer-BioNTech. As the COVID-19 pandemic evolves in China after the country abandoned its zero-COVID policy in December, domestic companies like CanSino are racing to develop mRNA COVID vaccines. The country - which experienced a wave of infections across its 1.4 billion population after the sudden relaxation of COVID restrictions - has so far declined to use mRNA vaccines from abroad, and has yet to approve a domestic one that uses the technology.

Yahoo | February 3, 2023

Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?

It's safe to go bargain-hunting again. Just make sure the bargain is a stock you actually want to own for the long haul.

Yahoo | February 3, 2023

Pharma Stock Roundup: MRK, LLY, PFE Q4 Results, J&J's Loss in Talc Lawsuits

Pfizer (PFE), Merck (MRK), Eli Lilly (LLY) and others report fourth-quarter results. An appeals court dismisses J&J's (JNJ) bankruptcy filing related to its talc lawsuits.

Yahoo | February 3, 2023

Regeneron’s Earnings Beat Forecasts, With No Sales of Covid-19 Treatment

The pharmaceuticals company's total revenue dropped by 31% to $3.41 billion but beat the FactSet consensus of $3.13 billion.

Yahoo | February 3, 2023

COVID is 'pretty much out of the models' for pharma companies: Wells Fargo analyst

Companies whose businesses were buoyed or boosted by Covid product demand are facing a cliff in 2023, and will have to pivot to more traditional strategies.

Yahoo | February 2, 2023

Bristol-Myers (BMY) Q4 Earnings Top, Revlimid Generic Impact Sales

Bristol-Myers' (BMY) fourth-quarter 2022 earnings beat estimates, while sales declined year over year due to generic erosion for oncology drug Revlimid.

Yahoo | February 2, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5102 seconds.